Scarica l'app Stockscreener
123.44
0.05%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NUVL Giù?
Forum
Previsione
Nuvalent Inc Borsa (NUVL) Ultime notizie
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal - Streetwise Reports
AASTOCKS Financial NewsNuvalent, Inc. (NUVL) - AASTOCKS.com
GSK agrees to acquire Nuvalent, Inc. - Pennsylvania Business Report -
Halper Sadeh LLC is Investigating Whether DAN, NUVL, SUNE, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
GSK in talks to buy Nuvalent for more than $9 billion: FT - MSN
GSK To Acquire Nuvalent In Largest Deal In Over A Decade – Merger Arbitrage Mondays (NYSE:GSK) - Seeking Alpha
GSK buys Nuvalent for $10.6 billion in major cancer push - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Assessing the 3.96% Potential Upside Amidst Biotech Innovation - DirectorsTalk Interviews
Herbert Smith Freehills Kramer advises on the financing for GSK plc's US$10.6 billion acquisition of Nuvalent Inc. - Legal Desire Media and Insights
NUVL stock surges 39% premarket – why is GSK buying this Boston-based oncology company? - MSN
GSK to Acquire Nuvalent for $10.6 Billion - GuruFocus
The week in pharma: action, reaction and insight – week to June 12, 2026 - The Pharma Letter
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent - GuruFocus
Patent cliff predators: GSK acquires Nuvalent for $10.6 billion - MSN
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK - MSN
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? - TradingView
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $124 to $126 - Moomoo
Nuvalent (NUVL) CDO sells 20,000 shares, exercises options - Stock Titan
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors - Seeking Alpha
GSK To Acquire Nuvalent for $10.6 Bn - DCAT Value Chain Insights
GSK to acquire Nuvalent for $10.6bn ahead of patent cliff - EMJ
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - MSN
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - Investing.com
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - MarketBeat
Slaughters, Davis Polk, Ropes line up on GSK’s $10.6bn biotech buy - Non-Billable
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - TradingView
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) - Yahoo Finance UK
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 - CHEManager
GSK Acquires Nuvalent To Maximise Cancer Treatments - Healthcare Digital
GSK Announces Record $10.6 Billion Acquisition of Nuvalent to Rebuild Oncology Portfolio - IndexBox
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal By Reuters - Investing.com
Investigation launched into Nuvalent's $10.6B deal with GSK over possible board breaches and unfair terms - Pluang
GSK to acquire Nuvalent for $10.6 billion in cash deal - scanx.trade
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK - BioSpace
GSK says AI is reshaping drug pipeline as Nuvalent deal hits shares - MSN
GSK makes $10.6B move for Nuvalent to boost cancer pipeline - MSN
GSK strikes deal to buy lung cancer drugmaker Nuvalent for $10.6bn - MSN
GSK to buy Nuvalent for $10.6 billion in oncology push - MSN
GSK plc to pursue cash tender offer for Nuvalent (NASDAQ: NUVL) - Stock Titan
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments - Genetic Engineering and Biotechnology News
GSK’s US$10.6b Nuvalent Purchase Recasts Oncology And Future Revenue Mix - simplywall.st
GSK Enters Agreement to Acquire Nuvalent Inc June 10, 2026 - James Sharp & Co.
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc.NUVL - Business Wire
GSK advances oncology efforts with $10.6bn Nuvalent acquisition - European Pharmaceutical Review
Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
GSK Acquires Nuvalent for $10.6 Billion in Lung Cancer Push - PharmTech.com
GSK to Acquire U.S. Biotech Firm Nuvalent for $10.6bn in Largest Pharma Deal in a Decade - Tekedia
Bernstein reiterates Nuvalent stock rating on GSK acquisition - Investing.com
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
GSK's $10.6B Nuvalent buy gains analyst backing for lung cancer growth amid HIV patent worries - Pluang
GSK's Nuvalent Deal Lays Groundwork for Future Launch of Lung-Cancer Drug -- Market Talk - Moomoo
1.79%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):